

**RUBRA MEDICAMENTS LIMITED**

Unaudited financial results for the quarter ended 30th September 2015

PART I		Rs. In Lakhs					
Particulars	3 Months Ended 30.09.2015	3 Months Ended 30.06.2015	3 Months Ended 30.09.2014	6 Months Ended 30.09.2015	Corresponding 6 Months Ended 30.09.2014	Year to date figures for the previous year ended 31.03.2015	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
<b>1 Income From Operations</b>							
(a) Income from Operations	6.12	-	-	6.12	-	-	
(b) Other operating Income	-	-	-	-	-	-	
<b>Total Income from Operations (net)</b>	<b>6.12</b>	<b>-</b>	<b>-</b>	<b>6.12</b>	<b>-</b>	<b>-</b>	
<b>2 Expenditure</b>							
a. Cost of material consumed	-	-	-	-	-	-	
b. Purchases of Stock-in-trade	2.06	-	-	2.06	-	-	
c. Change in inventories of finished goods, Work-in-Progress and stock-in-trade	-	-	-	-	-	-	
d. Employee benefits expenses	0.45	0.45	-	0.90	-	0.42	
e. Depreciation & Amortisation expenses	-	-	-	-	-	-	
f. Other Expenses	3.44	0.92	1.42	4.36	3.93	7.06	
<b>Total Expenses</b>	<b>5.95</b>	<b>1.37</b>	<b>1.42</b>	<b>7.32</b>	<b>3.93</b>	<b>7.48</b>	
Profit from Operations before Other Income, Finance Cost and Exceptional Items (1-2)	0.17	(1.37)	(1.42)	(1.20)	(3.93)	(7.48)	
4 Other Income	-	-	-	-	-	-	
5 Profit from ordinary activities before Finance Cost and Exceptional Items (3+4)	0.17	(1.37)	(1.42)	(1.20)	(3.93)	(7.48)	
6 Finance Costs	-	-	-	-	-	-	
7 Profit from ordinary activities after Finance Costs but before Exceptional Items (5-6)	0.17	(1.37)	(1.42)	(1.20)	(3.93)	(7.48)	
8 Exceptional Items	-	-	-	-	-	-	
9 Profit/(Loss) from ordinary activities before Tax (7+8)	0.17	(1.37)	(1.42)	(1.20)	(3.93)	(7.48)	
10 Tax Expenses	-	-	-	-	-	-	
11 Profit/(Loss) from Ordinary activities After Tax (9-10)	0.17	(1.37)	(1.42)	(1.20)	(3.93)	(7.48)	
12 Extraordinary Items (Net of Tax)	-	-	-	-	-	-	
<b>13 Net Profit / (Loss) for the period (11-12)</b>	<b>0.17</b>	<b>(1.37)</b>	<b>(1.42)</b>	<b>(1.20)</b>	<b>(3.93)</b>	<b>(7.48)</b>	
14 Paid-up Equity Share Capital (Face Value Rs.10/- Each)	546.83	546.83	546.83	546.83	546.83	546.83	
15 Reserve excluding revaluation reserves						(507.75)	
16 Earning per Share (Basic and diluted)*	0.00	(0.00)	(0.00)	(0.00)	(0.01)	(0.01)	
* Not Annualised							

PART II							
A	PARTICULARS OF SHAREHOLDINGS						
1	Public Shareholding						
	-Number of Shares	54,65,300	54,65,300	54,65,300	54,65,300	54,65,300	54,65,300
	- Percentage of shareholding	99.95	99.95	99.95	99.95	99.95	99.95
2	Promoter & Promoter Group Shareholding						
	a) Pledged / Encumbered						
	-Number of Shares	-	-	-	-	-	-
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
	Percentage of Shares (as a % of the total share capital of the Company)	-	-	-	-	-	-
	b) Non-Encumbered						
	-Number of Shares	3000	3000	3000	3000	3000	3000
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	Percentage of Shares (as a % of the total share capital of the Company)	0.05	0.05	0.05	0.05	0.05	0.05
	Particulars						
B	INVESTOR COMPLAINTS						
	Pending at the beginning of the quarter	0	0	0	0	0	0
	Received during the quarter	0	0	0	0	0	0
	Disposed of during the quarter	0	0	0	0	0	0
	Remaining unresolved at the end of the quarter	0	0	0	0	0	0

Notes:

- The above results were reviewed by the Audit Committee of the Board of Directors in their meeting held today
- The previous periods figures have been regrouped wherever necessary.

Place: Mumbai  
Date : 14/11/2015

For Rubra Medicaments Limited

  
Director

**RUBRA MEDICAMENTS LIMITED**  
**STATEMENT OF ASSETS AND LIABILITIES**

A	EQUITY AND LIABILITIES	As on September 30, 2015	As on March 31, 2015
<b>1</b>	<b>Shareholders Funds</b>		
	(a) Share Capital	546,83,000	546,83,000
	(b) Reserves and Surplus	(508,94,635)	(507,74,820)
	(c) Money received against share warrants	-	
	<b>Sub-total - Shareholders' funds</b>	<b>37,88,365</b>	39,08,180
<b>2</b>	<b>Share application money pending allotment</b>	-	-
<b>3</b>	<b>Minority interest</b>	-	-
<b>4</b>	<b>Non-current liabilities</b>		
	(a) Long-term borrowings	-	-
	(b) Deferred tax liabilities (net)	7,46,257	7,46,257
	(c) Other long-term liabilities	-	-
	(d) Long-term provisions	-	-
	<b>Sub-total - Non-current liabilities</b>	<b>7,46,257</b>	<b>7,46,257</b>
<b>5</b>	<b>Current liabilities</b>		
	(a) Short-term borrowings	-	-
	(b) Trade payables	-	-
	(c) Other current liabilities	-	-
	(d) Short-term provisions	-	-
	<b>Sub-total - Current liabilities</b>	-	-
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>45,34,622</b>	<b>46,54,437</b>
<b>B</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current assets</b>		
	(a) Fixed assets	-	-
	(b) Goodwill on consolidation	-	-
	(c) Non-current investments	-	-
	(d) Deferred tax assets (net)	-	-
	(e) Long-term loans and advances	32,82,070	30,54,070
	(f) Other non-current assets	1,68,819	1,68,819
	<b>Sub-total - Non-current assets</b>	<b>34,50,889</b>	<b>32,22,889</b>
<b>2</b>	<b>Current Assets</b>		
	(a) Current investments	-	-
	(b) Inventories	-	-
	(c) Trade receivables	1,77,269	1,77,269
	(d) Cash and cash equivalents	9,06,464	12,54,279
	(e) Short-term loans and advances	-	-
	(f) Other current assets	-	-
	<b>Sub-total - Current assets</b>	<b>10,83,733</b>	<b>14,31,548</b>
	<b>TOTAL - ASSETS</b>	<b>45,34,622</b>	<b>46,54,437</b>



**Limited Review Report of the Auditors**

Review Report

To,  
The Board of Directors  
Rubra Medicaments Limited  
Hyderabad

**Sub: Limited Review Report**

We have reviewed the accompanying statement of unaudited financial results of **Rubra Medicaments Limited** for the period ended **September 30, 2015** except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards<sup>6</sup> and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Prakash Modi & Associates  
Chartered Accountants  
FRN: 116900W

*Prakash Modi*

**Prakash Modi**  
Partner  
Mem No. 101463



Place: Mumbai  
Dated: 14<sup>th</sup> November 2015